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Abstract: Anti-inﬂ  ammatory drugs for treatment and prevention of Alzheimer’s disease have 
to date proved disappointing, including a large study of low-dose prednisone, but higher dose 
steroids signiﬁ  cantly reduced amyloid secretion in a small series of nondemented patients. In 
addition, there is a case report of a patient with amyloid angiopathy who had complete remission 
from two doses of dexamethasone, and very high dose steroids are already used for systemic 
amyloidosis. This paper presents the hypothesis that pulse-dosed intrathecal methylpredniso-
lone or dexamethasone will produce detectable slowing of Alzheimer’s progression, additive 
to that obtained with cholinesterase inhibitors and memantine. A protocol based on treatment 
regimens for multiple sclerosis and central nervous system lupus is outlined, to serve as a basis 
for formulating clinical trials. Ultimately intrathecal corticosteroids might become part of a 
multi-agent regimen for Alzheimer’s disease and also have application for other neurodegen-
erative disorders.
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Background
Epidemiological evidence suggests that drugs which counteract inflammation 
might have efﬁ  cacy for the prevention and treatment of Alzheimer’s disease, but 
up to now clinical trials have failed to show any clear-cut beneﬁ  ts for nonsteroidal 
anti-inﬂ  ammatory drugs (NSAIDs), hydroxychloroquine, anti-leprosy agents or 
prednisone (Endoh et al 1999; Aisen et al 2000; van Gool et al 2001; ADAPT et al 
2007). In the case of prednisone, however, it may be that much higher doses might 
be effective where lower doses were not. In the largest clinical trial to date, patients 
were given prednisone starting at 20 mg per day for one month, followed by one 
year at 10 mg daily and then tapering off over another 4 months (Aisen et al 2000). 
By contrast, in a series of 16 nondemented patients aged 25 to 82 who were given 
prednisolone 30–60 mg per day for at least month for treatment of various condi-
tions, there was signiﬁ  cant reduction in cerebrospinal ﬂ  uid amyloid beta peptides in 
15 out of 16 patients, up to about a 50% decline for patients receiving 50 and 60 mg 
of prednisolone (Tokuda et al 2002). If amyloid is indeed a cause of Alzheimer’s 
disease (Hardy 2006), the above data suggests high dose steroids could suppress 
Alzheimer’s disease by reducing amyloid. Along the same lines, there is a report 
of a patient where two single doses of dexamethasone 4 mg completely suppressed 
amyloid angiopathy, reversed white matter changes on brain imaging, and restored 
cognitive function (Harkness et al 2004). In that patient, 8 mg of dexamethasone would 
correspond to 80 mg of prednisone, or four times the starting dose of prednisone used 
in the Alzheimer’s disease clinical trial but given in a single dose.
If the above line of reasoning is on the right track, it is important to note that high 
dose corticosteroids are already used clinically for treatment of primary systemic 
amyloidosis, in amounts orders of magnitude greater than those used in the Alzheimer’s Neuropsychiatric Disease and Treatment 2008:4(5) 832
Alisky
disease trial. For example, in one recently published study of 
a regimen combining dexamethasone and interferon, patients 
were given several days of dexamethasone in an amount of 
40 mg per day, which would be equivalent to 400 mg of 
prednisone daily (Dhodapkar et al 2004). Even if amyloid 
is only a marker, not a cause, for Alzheimer’s disease (Lee 
2006), high-dose corticosteroids could have beneficial 
effects by reducing inﬂ  ammatory cytokines, which have been 
strongly linked to Alzheimer’s disease pathogenesis (Town 
and Nikolic 2005; Cagnin et al 2006; Galimberti et al 2006; 
McGeer et al 2006; Rota et al 2006). Finally, there is a case 
report of a 64-year-old man with multiple myeloma who had 
a temporary remission of Alzheimer’s disease while receiving 
chemotherapy with vincristine, carmustine, melphalan, 
cyclophosphamide, and prednisone (Keimowitz 1997).
Obviously megadose steroids or cytotoxic chemotherapy 
as a treatment for Alzheimer’s disease would be hard to jus-
tify, but if one can knock down amyloid production, inﬂ  am-
mation or both with corticosteroids alone, there should be 
at least some therapeutic effects. The key is delivering high 
enough doses of corticosteroids to have efﬁ  cacy without 
devastating or killing patients with steroid-induced side 
effects in the process. Building on several case reports of 
patients with central nervous system lupus erythematosus 
and multiple sclerosis who responded to intrathecal pred-
nisolone, dexamethasone, or triamcinalone after failing oral 
and intravenous steroids (Funauchi et al 2003; Hellwig et al 
2004, 2006), this paper proposes that a similar therapeutic 
strategy could be pursued for patients with Alzheimer’s 
disease. Studies in rhesus monkeys and pigs indicate that 
that intrathecal steroids maximize biodistribution within the 
brain and minimize it within the rest of the body (Marynick 
et al 1976; Koszdin et al 2000).
Presentation of the hypothesis
A short pulse of high dose intrathecal methylprednisolone, 
dexamethasone or triamcinalone will result in detectable slowing 
of Alzheimer’s disease as assessed by neuropsychological 
testing, cerebrospinal ﬂ  uid studies and functional brain 
imaging. It is further predicted that this route of administra-
tion will minimize the risk of steroid-induced side effects, 
which include diabetes, cataracts, glaucoma, poor wound 
healing, myopathy, increased susceptibility to infection, 
osteoporosis and altered fat distribution, based on the 
premise that the bioavailability of steroids would be almost 
exclusively within the central nervous system. Central ner-
vous system side effects may be more difﬁ  cult to control. 
Steroid-induced dementia that remits once steroids are 
stopped has been described in case reports (Varney 1997; 
Sacks and Shulman 2005), but memantine, a noncompetitive 
antagonist of N-methyl-D-aspartate glutamate receptors, 
should reduce or eliminate this risk. Memantine, which 
acts by protecting against excitoxic neuronal cell death, is 
already a mainstay of treatment for Alzheimer’s disease, 
with disease modifying activity that is maximized when 
given alongside cholinesterase inhibitors (Tariot et al 
2004). Corticosteroids down-regulate glutamate transporter 
protein in microglia (Jacobsson et al 2006), which in turn 
increases excitoxicity, so memantine which blocks glutamate 
excitotoxicty would seem to be ideal for preventing this 
problem. Cholinesterase inhibitors should provide further 
protection against steroid-induced dementia. These agents 
improve learning and memory by increasing synaptic levels 
of acetylcholine, and cholinesterase inhibitors produce symp-
tomatic improvement not only for Alzheimer’s disease but 
vascular, multiple sclerosis, Parkinsonian, and Lewy body 
dementias and delirium. They in essence boost cognitive 
reserve to cope with cognitive impairment no matter what 
the etiology, which would presumably include the minority 
of patients who have cognitive impairment speciﬁ  cally from 
steroids. Thus, by doing all pulse dose steroid regimens 
alongside both cholinesterase inhibitors and memantine, it 
is predicted that there will be no worsening of dementia but 
rather additive effects on top of the beneﬁ  ts of cholinesterase 
inhibitors and memantine have on their own.
Testing the hypothesis
A protocol is outlined here based on regimens described 
for central nervous system lupus and multiple sclerosis, to 
be used as a starting point for designing future clinical trials. 
Investigators should follow all recommended guidelines 
for research involving human subjects, such as institutional 
review board approval and informed consent. After obtaining 
a baseline positron emission tomography (PET) scan and 
neuropsychological tests, patients with early Alzheimer’s dis-
ease already taking a cholinesterase inhibitor and memantine 
would be given six intrathecal injections of 10 mg of dexameth-
asone, 100 mg of prednisolone, or 40 mg triamcinalone. Intra-
thecal injections can be done in the ofﬁ  ce with a bedside spinal 
tap or under ﬂ  uoroscopic guidance, if desired. Patients should 
be followed for at least one year in the initial study, repeating 
PET scans, cerebrospinal ﬂ  uid studies, and neuropsychological 
testing at the end of the study. Subsequently the patients could 
be followed out over years and decades. PET scanning has 
emerged as an important modality for studying Alzheimer’s 
disease and its response to treatment (Alexander et al 2002). Neuropsychiatric Disease and Treatment 2008:4(5) 833
Intrathecal corticosteroids might slow Alzheimer’s disease progression
Alongside functional brain imaging, cerebrospinal ﬂ  uid should 
be assayed for amyloid peptide and other Alzheimer’s disease 
biomarkers, such as neural thread protein (Chong et al 1992; 
Mrak and Grifﬁ  n 2005). It would be predicted that levels of 
these biomarkers should fall over time, if steroids indeed have 
efﬁ  cacy for halting dementia progression. Studies should focus 
on patients with the earliest signs of cognitive impairment so 
that they can be followed for longer periods of time. Also, 
there may be a window of opportunity for use of steroids 
only earlier in the disease process. Many of the inﬂ  ammatory 
cytokines peak with mild cognitive impairment and early 
Alzheimer’s disease and are actually declining by the late 
stages (Galimberti et al 2006).
Concluding remarks
Validation of the proposed hypothesis could be an important 
step towards the ultimate aim of curing Alzheimer’s disease. 
Pulse dosed intrathecal corticosteroids might become part 
of a future multi-agent regimen for halting Alzheimer’s 
disease progression, along-side cholinesterase inhibitors, 
memantine, and other drugs currently under investigation. 
Given that activated microglia are thought to play a role in 
the pathogenesis of other neurodegnerative diseases such 
as Parkinson’s disease, amyotrophic lateral sclerosis and 
HIV dementia (Wojtera et al 2005), success of intrathecal 
corticosteroids for Alzheimer’s disease would encourage 
trials for these other disorders. For all these reasons, I am 
presenting this idea here for maximum exposure to the 
widest possible interested audience. Andiamo avanti (let us 
go forward).
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